Worth reading
61In focus
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Decision and Details
United States Patent and Trademark Office (examination by the patent offices of each country)U.S. patent allowance for IRAK-M protein degraders (heterocyclic compounds)
Decision30 July 2026 (date notification was received)
ImplementationU.S. patent rights are expected to arise once the patent fee is paid following the patent allowance and the patent is registered and issued.
Going forwardPay the patent fee and have the patent registered and issued; continue examination in other countries and regions; establish a foundation for the research and development of the pipeline, including FIM-001, and future commercialization and partnering.
Quantity / scaleApplication No.: 17/630,203; multiple novel compounds encompassing FIM-001 and related compounds
Reason
To further strengthen the U.S. intellectual property rights for the group of compounds including FIM-001; as part of the national-phase filings based on the international application
Impact on Business Performance
No impact on the Company's consolidated financial results for the fiscal year ending December 2026
| Item | Details |
|---|---|
| Matter Covered | U.S. patent allowance for IRAK-M protein degraders (heterocyclic compounds) |
| Decision-Making Body | United States Patent and Trademark Office (examination by the patent offices of each country) |
| Decision Date | 30 July 2026 (date notification was received) |
| Implementation Date | U.S. patent rights are expected to arise once the patent fee is paid following the patent allowance and the patent is registered and issued. |
| Quantity / scale | Application No.: 17/630,203; multiple novel compounds encompassing FIM-001 and related compounds |
| Impact on Business Performance | No impact on the Company's consolidated financial results for the fiscal year ending December 2026 |
| Reason | To further strengthen the U.S. intellectual property rights for the group of compounds including FIM-001; as part of the national-phase filings based on the international application |
| Related previous disclosures | Patent allowance in Japan in January 2026 (title: Not disclosed) |
| Future plans | Pay the patent fee and have the patent registered and issued; continue examination in other countries and regions; establish a foundation for the research and development of the pipeline, including FIM-001, and future commercialization and partnering. |
Items this document does not state (3)
Period CoveredAmountGoverning Rule
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To further strengthen the U.S. intellectual property rights for the group of compounds including FIM-001.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.